Docetaxel Injection, Solution
Product Images NDC 0409-1732

17 FDA label images from Hospira, Inc. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 17 technical images submitted to the FDA as part of the official labeling for Docetaxel (NDC 0409-1732). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Hospira, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Docetaxel 01)

Chemical Structure (Docetaxel 01)
Chemical structure of the active ingredient Docetaxel anhydrous, shown as a detailed 2D molecular diagram with atoms, bonds, and stereochemistry.*
FDA Label Image

Figure 1 (Docetaxel 02)

Figure 1 (Docetaxel 02)
A line graph showing disease-free survival (DFS) probability percentages over time in months. Two treatment groups, TAC and FAC, are compared with lines illustrating the decline in DFS probability over approximately 66 months, with TAC generally showing higher DFS probability than FAC throughout the period.*
FDA Label Image

Figure 2 (Docetaxel 03)

Figure 2 (Docetaxel 03)
A line graph depicting survival probability (%) over survival time in months, comparing two groups labeled TAC and FAC. The x-axis shows time from 0 to 66 months, and the y-axis shows survival probability from 0% to 100%. Both groups demonstrate gradually decreasing survival probability over time, with TAC maintaining slightly higher survival rates than FAC toward the end of the period.*
FDA Label Image

Figure 3 (Docetaxel 04)

Figure 3 (Docetaxel 04)
A Kaplan-Meier survival curve chart showing cumulative probability versus survival time in months. The chart compares two groups labeled T75 and BSC, illustrating their overall survival with a reported log-rank p-value of 0.010, indicating a statistical difference in survival between the groups.*
FDA Label Image

Figure 4 (Docetaxel 05)

Figure 4 (Docetaxel 05)
A survival curve chart depicting cumulative probability versus survival time in months, comparing two groups labeled T75 and V/I. The chart includes a statistical note on overall survival with a log-rank p-value of 0.13.*
FDA Label Image

Figure 5 (Docetaxel 06)

Figure 5 (Docetaxel 06)
A survival probability chart showing two survival curves over a 30-month period. The x-axis represents survival time in months, and the y-axis represents survival probability. Two groups are compared, indicated as T75 q3w and M q3w, with T75 q3w showing higher survival probability over time.*
FDA Label Image

Figure 6 (Docetaxel 07)

Figure 6 (Docetaxel 07)
A Kaplan-Meier survival curve comparing two treatment groups labeled TCF and CF. The y-axis represents probability (%) and the x-axis represents time in months, spanning from 0 to 24 months. Two lines illustrate the survival probability over time for each group, showing a decrease in probability as time progresses.*
FDA Label Image

Figure 7 (Docetaxel 08)

Figure 7 (Docetaxel 08)
A survival probability chart showing two survival curves labeled TCF and CF over a period of 36 months. The vertical axis represents survival probability (%) from 0 to 100, and the horizontal axis represents survival time in months from 0 to 36. The graph compares survival probabilities between the two groups over time.*
FDA Label Image

Figure 8 (Docetaxel 09)

Figure 8 (Docetaxel 09)
A Kaplan-Meier plot depicting progression-free survival (PFS) probability (%) on the y-axis over time in months on the x-axis. Two treatment groups, TPF and PF, are compared, showing the change in PFS probability up to 42 months. The TPF group has a higher PFS probability over time compared to the PF group.*
FDA Label Image

Figure 9 (Docetaxel 10)

Figure 9 (Docetaxel 10)
A survival curve chart depicting survival probability (%) over survival time in months. Two groups are compared: TPF (solid line) and PF (dashed line). The vertical axis shows survival probability from 0 to 100%, and the horizontal axis shows time from 0 to 72 months, illustrating changes in survival probability over time for both groups.*
FDA Label Image

Figure 10 (Docetaxel 11)

Figure 10 (Docetaxel 11)
A survival curve chart depicting survival probability (%) over time in months. It compares two treatment groups, TPF (n=255) and PF (n=246), showing their respective patient survival trends over a period of up to 72 months. The chart includes the number of patients at risk at various time points for both groups below the x-axis.*
FDA Label Image

Logo (Docetaxel 12)

FDA Label Image

Logo (Docetaxel 13)

FDA Label Image

Principal Display Panel (80 mg/8 mL Vial Label)

Principal Display Panel (80 mg/8 mL Vial Label)
Label for Docetaxel Injection USP 20 mg/2 mL (10 mg/mL) intravenous solution by Hospira, Inc. The single-dose vial label includes dosage, storage instructions (20° to 25°C), warnings for cytotoxic use, and preparation directions. It shows barcodes, lot and expiration placeholders, and distributor information.*
FDA Label Image

Principal Display Panel (80 mg/8 mL Vial Carton)

Principal Display Panel (80 mg/8 mL Vial Carton)
Packaging label for Docetaxel Injection, USP, 20 mg/2 mL (10 mg/mL) ready-to-add intravenous infusion solution. The label indicates a single-dose vial, distributed by Hospira, Inc., with usage instructions and warnings, including a caution for cytotoxicity and a reminder to keep out of reach of children.*
FDA Label Image

Principal Display Panel (160 mg/16 mL Vial Label)

Principal Display Panel (160 mg/16 mL Vial Label)
Label for Docetaxel Injection, USP 80 mg/8 mL (10 mg/mL) multiple-dose vial. It is for intravenous use only and includes a warning about cytotoxic agents. Distributed by Hospira, Inc. The label lists active ingredients, storage instructions, and a note to check the package insert for dosage and preparation details.*
FDA Label Image

Principal Display Panel (160 mg/16 mL Vial Carton)

Principal Display Panel (160 mg/16 mL Vial Carton)
Packaging label for Docetaxel Injection, USP 80 mg/8 mL (10 mg/mL) intravenous infusion solution by Hospira, Inc. The label indicates it is ready to add to infusion solution and is a cytotoxic agent. The package is for a multiple-dose vial, with warnings, storage instructions, and a note to check concentration prior to preparation.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.